San Antonio Breast Cancer Symposium
|
|
- Charlene Booth
- 7 years ago
- Views:
Transcription
1 Tuesday, December 8, EDUCATION SESSIONS 12:35 p.m. Careers in Translational Research Geoffrey Shapiro, MD, PhD Director, Early Drug Development Center Clinical Director, Center for DNA Damage and Repair Senior Physician Wednesday, December 9, December 8-12, EDUCATION SESSIONS 8:15 a.m. Critical Decision Making in Radiation Therapy for in Jay R. Harris, MD Chair of the Department of Radiation Oncology at Dana- Farber/Brigham and Women's Cancer Center (DF/BWCC) 2:15 p.m. Hacking the Hormone Code in ER+ Myles A. Brown, MD Physician Director, Center for Functional Cancer Epigenetics MINI-SYMPOSIUM 1 2:15 p.m. Beyond CDK 4/6: Targeting additional cell cycle and transcriptional CDKs in breast cancer Geoffrey Shapiro, MD, PhD Director, Early Drug Development Center Clinical Director, Center for DNA Damage and Repair Senior Physician POSTER SESSION 1 The incidence of and survival after breast cancer recurrence P Michael Hassett, MD Page 1
2 Wednesday, December 9, POSTER SESSION 1 (continued) Predisposing germline mutations in a clinic based breast cancer (BC) population P Judy Garber, MD, MPH December 8-12, Factors associated with delays in chemotherapy initiation among patients with breast cancer P Craig Bunnell, MD, MPH, MBA ONGOING CLINICAL TRIALS SESSION 1 A phase III randomized trial of atezolizumab in combination with nab-paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mtnbc) OT Eric Winer, MD A phase 2 study of abemaciclib in patients with brain metastases secondary to hormone receptor positive breast cancer OT Sara Tolaney MD, MPH PALLAS: PAlbociclib Collaborative Adjuvant Study: A randomized phase 3 trial of palbociclib with adjuvant endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer OT Erica Mayer MD, MPH Page 2
3 Thursday, December 10, POSTER SESSION 2 7:30-9:00 a.m. Implementation of a breast/reconstructive surgery coordinator to reduce preoperative delays for patients undergoing mastectomy with immediate reconstruction P Mehra Golshan, MD, FACS December 8-12, Immune activation signatures identify a subset of ER+ breast cancers with increased pathologic complete response to neoadjuvant chemotherapy P Daniel Stover, MD Exploring bazedoxifene and palbociclib as potential therapeutic strategies for overcoming ESR1-mediated endocrine resistance P Rinath M. Jeselsohn, MD POSTER DISCUSSION 3 5:00 p.m. PD3-5: Whole exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients with or without prior trastuzumab (T): A correlative analysis of TBCRC003 Nikhil Wagle, MD Page 3
4 Thursday, December 10, ONGOING CLINICAL TRIALS SESSION 2 Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER+/AR+ breast cancer (BC) in postmenopausal (PM) women OT December 8-12, The metastatic breast cancer project: A national direct-topatient research initiative to accelerate genomics research OT Nikhil Wagle, MD Friday, December 11, POSTER SESSION 4 7:30-9:00 a.m. MRI changes in breast skin following preoperative therapy for inflammatory breast cancer (IBC) P Genetic predictors of chemotherapy-related amenorrhea P Ann Partridge MD, MPH Employment trends in young women following a breast cancer diagnosis P Ann Partridge MD, MPH. Page 4
5 Friday, December 11, POSTER SESSION 4 (Continued) GENERAL SESSION 5 10:30 a.m. Abemaciclib, an inhibitor of CDK4 and CDK6, combined with endocrine and HER2-targeted therapies for women with metastatic breast cancer P Sara Tolaney, MD, MPH December 8-12, POSTER SESSION 5 Trastuzumab emtansine improves overall survival versus treatment of physician s choice in patients with previously treated HER2-positive metastatic breast cancer: Final overall survival results from the phase 3 TH3RESA study Ian Krop, MD, PhD Incidence and prognostic importance of hyponatremia in a cohort of patients with breast cancer P Jorge Castillo, MD Medical Oncology Survival benefit needed to undergo chemotherapy: Patients and physicians preferences P Ann Partridge, MD, MPH What goes through your mind when you think about your medication? Thoughts about endocrine medication and treatment adherence P Ann Partridge, MD, MPH Page 5 POSTER DISCUSSION 6 Translational Genomics - Ballroom B Nikhil Wagle, MD, Co-Discussant
6 Friday, December 11, POSTER DISCUSSION 6 Translational Genomics - Ballroom B Nikhil Wagle, MD, Co-Discussant December 8-12, POSTER DISCUSSION 7 Clinical Applications of Hereditary Multigene Panels - Ballroom A Judy E. Garber, MD, MPH, Co-Discussant Saturday, December 12, POSTER SESSION 6 7:30-9:00 a.m. Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer P Tumor profiling of inflammatory breast cancer: Advancing the tools needed for precision medicine P :00 a.m. The Year in Review: Update on Basic Science Discoveries Myles A. Brown, MD Director, Center for Functional Cancer Epigenetics Page 6
Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America
Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions
More informationMechanism Of Action of Palbociclib & PFS Benefit
A Phase II Randomized Controlled Trial of Palbociclib & Tamoxifen/Fulvestrant in Postmenopausal Women and Men With Hormone-Receptor Positive, HER2- Negative Metastatic Breast Cancer (MBC) Protocol Chair:
More informationBreast Cancer Advances
Winter 2011 Breast Cancer Advances Page 2 Page 4 Page 5 Page 6 Page 7 Page 9 Advancement of Individualized, Personalized Surgery and Local Therapy for Breast Cancer to Minimize Treatment The Breast Surgical
More informationREFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC256CFR PUBLICAT ION DATE SEPTEMBER 2014 HER2-POSITIVE BREAST CANCER CHINA DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for HER2-Positive Breast Cancer in China Market
More informationMetastatic Breast Cancer 201. Carolyn B. Hendricks, MD October 29, 2011
Metastatic Breast Cancer 201 Carolyn B. Hendricks, MD October 29, 2011 Overview Is rebiopsy necessary at the time of recurrence or progression of disease? How dose a very aggressive treatment upfront compare
More informationSystemic Therapy for Patients With Advanced HER2-Positive Breast Cancer
Systemic Therapy for Patients With Advanced HER2-Positive Breast Cancer CLINICAL PRACTICE GUIDELINE www.asco.org/guidelines/treather2pos American Society of Clinical Oncology. All rights reserved. Introduction
More informationBreast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer. Kevin R. Fox, MD University of Pennsylvania
Breast Cancer Update 2014 Prevention, Risk, and Treatment of Early Stage Breast Cancer Kevin R. Fox, MD University of Pennsylvania Prevention of Breast Cancer Accepted treatments Tamoxifen (premenopausal
More informationALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
More informationRobert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationSAMO FoROMe Post-ESMO 2013 Breast Cancer
SAMO FoROMe Post-ESMO 2013 Breast Cancer Dr. med. Manuela Rabaglio Klinik und Poliklinik für Medizinische Onkologie Breast Cancer Track 300 Abstracts 142 Poster 11 Proffered paper 4 late breaking news
More informationESMO 2014 Summary Breast Cancer
ESMO 2014 Summary Breast Cancer 1 7. 1 0. 2 0 1 4 A N NA D U R I G OVA M E D I C A L O N CO LO GY U N I V E R S I T Y H O S P I TA L S O F G E N E VA Outline 1. Early Breast Cancer Her2+ Neoadjuvant: Lapatax
More informationBreast Cancer Treatment Guidelines
Breast Cancer Treatment Guidelines DCIS Stage 0 TisN0M0 Tamoxifen for 5 years for patients with ER positive tumors treated with: -Breast conservative therapy (lumpectomy) and radiation therapy -Excision
More informationBreakthrough Treatment Options for Breast Cancer
Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationAvastin in breast cancer: Summary of clinical data
Avastin in breast cancer: Summary of clinical data Worldwide, over one million people are diagnosed with breast cancer every year 1. It is the most frequently diagnosed cancer in women 1,2, and the leading
More informationTargeted Therapy What the Surgeon Needs to Know
Targeted Therapy What the Surgeon Needs to Know AATS Focus in Thoracic Surgery 2014 David R. Jones, M.D. Professor & Chief, Thoracic Surgery Memorial Sloan Kettering Cancer Center I have no disclosures
More informationRotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma
Rotation Specific Goals & Objectives: University Health Network-Princess Margaret Hospital/ Sunnybrook Breast/Melanoma Medical Expert: Breast Rotation Specific Competencies/Objectives 1.0 Medical History
More informationGoals and Objectives: Breast Cancer Service Department of Radiation Oncology
Goals and Objectives: Breast Cancer Service Department of Radiation Oncology The breast cancer service provides training in the diagnosis, management, treatment, and follow-up of breast malignancies, including
More informationBest of San Antonio Breast Cancer Symposium
Best of San Antonio Breast Cancer Symposium 11:45 am - 5:00 pm 5800 Rockside Woods Blvd. About the Course The San Antonio Breast Cancer Symposium is an international meeting of laboratory and clinical
More informationMiquel Àngel Seguí Palmer
Miquel Àngel Seguí Palmer HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ Breast Cancer is characterized by overexpression of HER2 receptors HER2+ status is associated with
More informationResumen Curricular de los Profesores. Jesse Boehm
Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub
More informationSommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle
Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of
More informationCellular, Molecular, and Biochemical Targets in Breast Cancer
Cellular, Molecular, and Biochemical Targets in Breast Cancer Kristy Kummerow Ingrid Meszoely December 12, 2012 VUMC Resident Bonus Conference One size fits all surgical treatment of breast cancer Wilhelm
More informationTreating Patients with Hormone Receptor Positive, HER2 Positive Operable or Locally Advanced Breast Cancer
Breast Studies Adjuvant therapy after surgery Her 2 positive Breast Cancer B 52 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients with Hormone
More informationOI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ
OI PARP ΑΝΑΣΤΟΛΕΙΣ ΣΤΟΝ ΚΑΡΚΙΝΟ ΤΟΥ ΜΑΣΤΟΥ ΝΙΚΟΛΑΙΔΗ ΑΔΑΜΑΝΤΙΑ ΠΑΘΟΛΟΓΟΣ-ΟΓΚΟΛΟΓΟΣ Β ΟΓΚΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ ΝΟΣ. ΜΗΤΕΡΑ Study Overview Inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase
More informationNEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
More informationGuide to Understanding Breast Cancer
An estimated 220,000 women in the United States are diagnosed with breast cancer each year, and one in eight will be diagnosed during their lifetime. While breast cancer is a serious disease, most patients
More informationA Decade of Innovation in Cancer
A Decade of Innovation in Cancer 2006 2016 A Decade of Innovation in Cancer A Decade of Innovation in Cancer: 2006-2016 4 Introduction 6 Metastatic Melanoma: Deeper Understanding of Disease Leads to Discoveries
More informationBreast Cancer in Young Women: Quality of Life and Survivorship
Breast Cancer in Young Women: Quality of Life and Survivorship Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute Brigham and Women s Hospital Harvard Medical School Breast Cancer in Young Women is
More informationBiomarker Trends in Breast Cancer Research
WHITE PAPER Biomarker Trends in Breast Cancer Research Jason Hill, PhD, Associate Director, External Science Affairs, Quintiles Quintiles examines the novel drug combinations and mechanisms of action that
More informationGilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University
Gilberto de Lima Lopes, MD, MBA, FAMS Chief Medical and Scientific Officer, Oncoclinicas Group Asst. Prof. of Oncology, Johns Hopkins University Assoc. Editor ASCO University and JGO Progress Against
More informationWhen it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month
For Immediate Release Oct. 8, 2012 When it comes to treating breast cancer, doing less does more October is Breast Cancer Awareness Month SEATTLE Oncologists and researchers are discovering that when it
More informationEffects of Herceptin on circulating tumor cells in HER2 positive early breast cancer
Effects of Herceptin on circulating tumor cells in HER2 positive early breast cancer J.-L. Zhang, Q. Yao, J.-H. Chen,Y. Wang, H. Wang, Q. Fan, R. Ling, J. Yi and L. Wang Xijing Hospital Vascular Endocrine
More informationBreast Cancer. CSC Cancer Experience Registry Member, breast cancer
ESSENTIALS Breast Cancer Take things one step at a time. Try not to be overwhelmed by the tidal wave of technical information coming your way. Finally you know your body best; you have to be your own advocate.
More informationLOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT
LOOKING FORWARD PUMA BIOTECHNOLOGY, INC. 2014 ANNUAL REPORT Puma Biotechnology, Inc. is a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of
More informationRecommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases
Recommendations on Disease Management for Patients with Advanced HER2-Positive Breast Cancer and Brain Metastases Clinical Practice Guideline www.asco.org/guidelines/her2brainmets American Society of Clinical
More informationMetastatic breast cancer represents an incurable condition associated with an average survival time of 18 to 24 months.
TACT-2C Trial A phase II randomized, open-label study evaluating the addiction of trastuzumabto (nabtm)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with
More informationProportion of patients with invasive breast cancer in whom ER, PR and/or
1.1.a. Proportion of patients with invasive breast cancer in whom ER, PR and/or HER2 status assessment were performed 1.1.b. Proportion of patients with invasive breast cancer in whom systemic treatment
More informationTeaching Medicine and Teaching Science: Is there a difference? From MD to PhD (Clinical Researcher) Ines Vaz Luis September 2013
Teaching Medicine and Teaching Science: Is there a difference? From MD to PhD (Clinical Researcher) Ines Vaz Luis September 2013 Disclosures I have no disclosures But. I have a WARNING: This talk is largely
More informationMetastatic Breast Cancer...
DIAGNOSIS: Metastatic Breast Cancer... What Does It Mean For You? A diagnosis of metastatic breast cancer can be frightening. It raises many questions and reminds us of days past when cancer was such a
More informationIntegrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
More informationApplications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities
Applications of comprehensive clinical genomic analysis in solid tumors: obstacles and opportunities Vincent A. Miller, M.D. Foundation Medicine, Inc. AACR Annual Meeting 2012 Current Concepts session
More informationRecommendations for the management of early breast cancer
Recommendations for the management of early breast cancer in women with an identified BRCA1 or BRCA2 gene mutation or at high risk of a gene mutation FEBRUARY 2014 Incorporates published evidence to August
More informationGUIDELINES ADJUVANT SYSTEMIC BREAST CANCER
GUIDELINES ADJUVANT SYSTEMIC BREAST CANCER Author: Dr Susan O Reilly On behalf of the Breast CNG Written: December 2008 Agreed at CNG: June 2009 & June 2010 Review due: June 2011 Guidelines Adjuvant Systemic
More information5.04.20. Perjeta. Perjeta (pertuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.20 Subject: Perjeta Page: 1 of 5 Last Review Date: June 19, 2015 Perjeta Description Perjeta (pertuzumab)
More informationProstate Cancer. Treatments as unique as you are
Prostate Cancer Treatments as unique as you are UCLA Prostate Cancer Program Prostate cancer is the second most common cancer among men. The UCLA Prostate Cancer Program brings together the elements essential
More informationPI3K signaling pathway a new target for breast cancer treatment
PI3K signaling pathway a new target for breast cancer treatment Introduction At the 37 th annual San Antonio Breast Cancer Symposium, SABCS, a number of interesting research trends, novelties as well as
More informationBreast. Patient information. cancer clinical pathway
Breast Patient information cancer clinical pathway This leaflet was written to properly inform people following breast cancer treatment plan. It doesn t replace the dialogue with healthcare staff; it rather
More informationFuture Directions in Clinical Research. Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center
Future Directions in Clinical Research Karen Kelly, MD Associate Director for Clinical Research UC Davis Cancer Center Outline 1. Status of Cancer Treatment 2. Overview of Clinical Research at UCDCC 3.
More informationCorporate Medical Policy
Corporate Medical Policy Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ado_trastuzumab_emtansine_(trastuzumab-dm1)_for_treatment_of_her-2_positivemalignancies
More informationUnderstanding Your Surgical Options For Breast Cancer
RADIATION THERAPY SYMPTOM MANAGEMENT CANCER INFORMATION Understanding Your Surgical Options For Breast Cancer In this booklet you will learn about: Role of surgery in breast cancer diagnosis and treatment
More informationWhat is breast cancer?
Breast Cancer What is breast cancer? Let us explain it to you. www.anticancerfund.org www.esmo.org ESMO/ACF Patient Guide Series based on the ESMO Clinical Practice Guidelines BREAST CANCER: A GUIDE FOR
More informationHigh Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem
High Grade Gliomas: Update in Treatment and Care Ryan T. Merrell, M.D. Clinical Assistant Professor of Neurology NorthShore University HealthSystem rmerrell@northshore.org Objectives Provide updates on
More informationtrastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd
trastuzumab, 600mg/5mL solution for injection (Herceptin ) SMC No. (928/13) Roche Products Ltd 06 December 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationMetastatic Melanoma What You Need to Know
ESSENTIALS Metastatic Melanoma Metastatic Melanoma What You Need to Know If you have metastatic melanoma, you may feel as though your life has been turned upside down. It s a serious disease, but patients
More informationInova. Breast Care Institute
Inova Breast Care Institute At the Inova Breast Care Institute, our commitment is to provide expert care for you, every step of the way. Our multidisciplinary team of more than 80 experts provides a full
More informationEverolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Everolimus plus exemestane for second-line endocrine treatment of oestrogen receptor positive metastatic breast cancer Everolimus plus exemestane for second-line
More informationPrognostic and Predictive Factors in Oncology. Mustafa Benekli, M.D.
Prognostic and Predictive Factors in Oncology Mustafa Benekli, M.D. NCI Definitions ESMO Course -Essentials of Medical Oncology -Istanbul 2 Prognostic factor: NCI Definition A situation or condition, or
More informationAsk Us About Clinical Trials
Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing
More informationChemotherapy or Not? Anthracycline or Not? Taxane or Not? Does Density Matter? Chemotherapy in Luminal Breast Cancer: Choice of Regimen.
Chemotherapy in Luminal Breast Cancer: Choice of Regimen Andrew D. Seidman, MD Attending Physician Breast Cancer Medicine Service Memorial Sloan Kettering Cancer Center Professor of Medicine Weill Cornell
More informationREFERENCE CODE GDHC92PIDR PUBLICATION DATE JANUARY 2015 HER2-NEGATIVE BREAST CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC92PIDR PUBLICATION DATE JANUARY 2015 HER2-NEGATIVE BREAST CANCER GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary HER2-Negative Breast Cancer: Key Metrics in the Eight
More informationDrug/Drug Combination: Bevacizumab in combination with chemotherapy
AHFS Final Determination of Medical Acceptance: Off-label Use of Bevacizumab in Combination with Chemotherapy for the Treatment of Metastatic Breast Cancer Previously Treated with Cytotoxic Chemotherapy
More informationProgress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
More informationNew Treatment Advances for Breast Cancer
New Treatment Advances for Breast Cancer Guest Expert: Lyndsay, MD Director of the Yale Cancer Center Breast Cancer Program Gina ng, MD www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center
More informationBreast cancer research and a changing treatment pathway
Breast cancer research and a changing treatment pathway Stuart McIntosh Clinical Senior Lecturer in Surgical Oncology, QUB Consultant Breast Surgeon, BCH What is the breast surgeon s role in 2016? Surgery
More informationUnderstanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide
Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide A diagnosis of breast cancer is never easy, but today there are more treatment options than ever before. A breast
More informationWhat is New in Oncology. Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals
What is New in Oncology Michael J Messino, MD Cancer Care of WNC An affiliate of Mission hospitals Personalized Medicine Personalized Genomics Genomic Medicine Precision Medicine Definition Application
More informationAdjuvant Endocrine Therapy in Breast Cancer: 2015 Update
Adjuvant Endocrine Therapy in Breast Cancer: 2015 Update Shannon Puhalla, MD Director, Breast Cancer Clinical Research Program Magee Womens Cancer Program University of Pittsburgh Cancer Institute Questions
More informationCancer Communication & Care Plan - We Learned How We Work
Communication & Care Plan for Breast Cancer Treatment Creating a Tool for Patient-Centered Care Laura Esserman, MD, MBA Director, UCSF Carol Franc Buck Breast Care Center Director, Cancer Center Clinical
More informationSubcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors. 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D.
Subcutaneous Testosterone-Anastrozole Therapy in Breast Cancer Survivors 2010 ASCO Breast Cancer Symposium Abstract 221 Rebecca L. Glaser M.D., FACS Learning Objectives After reading and reviewing this
More informationBreast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns
July 2013 Edition Vol. 7, Issue 7 Breast and Lung Cancer Biomarker Research at ASCO: Changing Treatment Patterns By Julie Katz, MPH, MPhil Biomarkers played a prominent role in the research presented in
More informationGuideline Development The American Society of Clinical Oncology
Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary
More informationBreast Health Program
Breast Health Program Working together, for your health. Breast Health Program The Breast Health Program at The University of Arizona Cancer Center offers patients a personalized approach to breast cancer,
More informationSECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR.
SECOND PRIMARY BREAST CANCERS FOLLOWING HAEMATOLOGIC MALIGNANCIES A CASE SERIES STUDY FARAH TANVEER PGY 3 DR.MEIR WETZLER DR. TRACEY O CONNOR RESEARCH QUESTON Patients with previously diagnosed hematologic
More informationYour Immune System & Lung Cancer Treatment
Your Immune System & Lung Cancer Treatment Immunotherapy and Lung Cancer Immunotherapy is quickly developing as an important approach to treating many forms of cancer, including lung cancer. Immunotherapy
More informationBREAST CANCER RISK ASSESSMENT AND PRIMARY PREVENTION FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1
FOR HIGH RISK PATIENTS, RACHEL CATHERINE JANKOWITZ, MD 1 Hello, my name is Rachel Jankowitz, I m an assistant professor of medicine in the Division of Hematology Oncology at the University of Pittsburgh
More informationEpidemiology. Breast Cancer Screening, Diagnosis, Biology and Long-Term Follow-Up EDUCATIONAL OBJECTIVES
Cancer Treatment Centers of America Breast Cancer: Screening, Diagnosis, Biology and Long-Term Follow-Up Presented to: Atlantic Regional Osteopathic Conference Presented by: Pamela Crilley, DO Date: April
More informationOvarian Cancer Genetic Testing: Why, When, How?
Ovarian Cancer Genetic Testing: Why, When, How? Jeffrey Dungan, MD Associate Professor Division of Clinical Genetics Department of Obstetrics & Gynecology Northwestern University Feinberg School of Medicine
More informationBreast Cancer Care & Research
Breast Cancer Care & Research Professor John FR Robertson University of Nottingham Nottingham City Hospital Breast Cancer (BC) 15,000 BC deaths in the UK each year 20% female cancer deaths 5% all female
More information7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
More informationTreatment of Metastatic Breast Cancer: Endocrine Therapies. Robert W. Carlson, M.D. Professor of Medicine Stanford University
Treatment of Metastatic Breast Cancer: Endocrine Therapies Robert W. Carlson, M.D. Professor of Medicine Stanford University MDACC Experience with FAC in Chemotherapy-Naive MBC Greenberg et al, J Clin
More informationInflammatory Breast Cancer
Inflammatory Breast Cancer This document briefly describes inflammatory breast cancer. For more comprehensive information on this and other types of breast cancer, please refer to our document called Breast
More informationKomorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
More informationNew Treatment Options for Breast Cancer
New Treatment Options for Breast Cancer Brandon Vakiner, PharmD., BCOP Clinical Pharmacy Specialist - Oncology The University of Iowa Hospitals and Clinics Assistant Professor (Clinical) University of
More informationInspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015
Inspira (Vineland/Woobury) Open Clinical Trials as of December 16, 2015 Advanced Refractory Solid Tumors or Lymphomas ECOG-ACRIN EAY131 (NCI CIRB) Targeted Therapy Directed by Genetic Testing in Treating
More informationST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival
ST JOSEPH REGIONAL HEALTH CENTER LUNG CANCER ANALYSIS Incidence, Diagnosis, Treatment and Survival It is logical that the Cancer Program Committee choose to review the Lung Site, as Lung is the second
More informationBreast Cancer. NCCN Guidelines for Patients. Version 2010. Made possible by a generous charitable contribution from Susan G. Komen for the Cure
Breast Cancer NCCN Guidelines for Patients Version 2010 Made possible by a generous charitable contribution from Susan G. Komen for the Cure Also available at NCCN.com Breast Cancer Table of Contents Map
More informationFlorida Breast Health Specialists Breast Cancer Information and Facts
Definition Breast cancer is a cancer that starts in the tissues of the breast. There are two main types of breast cancer: Ductal carcinoma starts in the tubes (ducts) that move milk from the breast to
More informationBig Data and Oncology Care Quality Improvement in the United States
Big Data and Oncology Care Quality Improvement in the United States Peter P. Yu, MD, FACP, FASCO President, American Society of Clinical Oncology Director of Cancer Research, Palo Alto Medical Foundation
More informationPHYSICIAN PROFILES. Dedicated to Discovery Committed to Care. www.dana-farber.org
PHYSICIAN PROFILES Dedicated to Discovery Committed to Care www.dana-farber.org Table of Contents About Dana-Farber Cancer Institute 3 Oncology Hospital 4 Breast Oncology 7 Cancer Genetics and Prevention
More informationOpportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests
Opportunities and Challenges in Translating Novel Discoveries into Useful Clinical Tests James H. Doroshow, M.D. NCI Deputy Director for Clinical and Translational Research NCI Workshop: Evidence Needed
More informationHereditary Multifocal Breast Cancer. Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center
Hereditary Multifocal Breast Cancer Farin Amersi M.D., F.A.C.S Division of Surgical Oncology Department of Surgery Cedar Sinai Medical Center CASE STUDY 30 year old Ashkenazi Jewish woman Nulliparous Felt
More informationReport series: General cancer information
Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for
More informationBreast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
More informationAmerican Cancer Society Extramural Grants
Page: 1 Doctoral Training Grant in Oncology Social Work Renewal (DSWR) DSWR-14-087-03 Blinka, Marcela, MSW MENTOR: BrintzenhofeSzoc, Karlynn, MSW, DSW, PhD The Catholic University of America National Catholic
More informationBreast cancer treatments
Breast cancer treatments i About us Breast Cancer Network Australia (BCNA) is the peak organisation for all people affected by breast cancer in Australia. We provide a range of free resources, including
More informationThe following information is only meant for people who have been diagnosed with advanced non-small cell
Important information for people with advanced non-small cell lung cancer The following information is only meant for people who have been diagnosed with advanced non-small cell lung cancer (NSCLC). NSCLC
More informationTemario- speakers. Management of the axilla in local and / or regional recurrence Manejo de la axila en la recurrencia local y / regional.
16.08.11 Henry Kuerer MD, PhD, FACS Director Breast SurgicalOncology University of Texas MD Anderson Cancer Center. Houston, TX Re-excision in local recurrence after conservative therapy Retumorectomía
More information1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1
1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY
More informationInvasive lobular breast cancer
Invasive lobular breast cancer This booklet is about invasive lobular breast cancer. It describes what invasive lobular breast cancer is, the symptoms, how it s diagnosed and possible treatments. Diagnosed
More information